Therapies targeting triple-negative breast cancer: a perspective on anti-FGFR
Triple-negative breast cancer (TNBC) is one of the subtypes with the worst prognosis due to tumour heterogeneity and lack of appropriate treatment. This condition is a consequence of the distinctive tumour microenvironment (TME). The TME is associated with factors such as the promotion of proliferat...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1415820/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850034389598076928 |
|---|---|
| author | Jinhao Chen Jinhao Chen Jinhao Chen Qianru Wang Qianru Wang Hongyan Wu Hongyan Wu Xiaofei Huang Xiaofei Huang Chunyu Cao Chunyu Cao |
| author_facet | Jinhao Chen Jinhao Chen Jinhao Chen Qianru Wang Qianru Wang Hongyan Wu Hongyan Wu Xiaofei Huang Xiaofei Huang Chunyu Cao Chunyu Cao |
| author_sort | Jinhao Chen |
| collection | DOAJ |
| description | Triple-negative breast cancer (TNBC) is one of the subtypes with the worst prognosis due to tumour heterogeneity and lack of appropriate treatment. This condition is a consequence of the distinctive tumour microenvironment (TME). The TME is associated with factors such as the promotion of proliferation, angiogenesis, inhibition of apoptosis, suppression of the immune system and drug resistance. Therefore, remodelling the TME is critical for the treatment of TNBC. A key role in the formation of the TME is played by the fibroblast growth factor/fibroblast growth factor receptor(FGF/FGFR) signalling pathway. Thus, the FGFRs may be a potential target for treating TNBC. Over-activated FGFRs promote growth, migration and drug resistance in TNBC by influencing the onset of TME events, tumour angiogenesis and immune rejection. A thorough comprehension of the FGF/FGFR signalling pathway’s mechanism of action in the development of TNBC could offer valuable insights for discovering new therapeutic strategies and drug targets. Inhibiting the FGF/FGFR axis could potentially hinder the growth of TNBC and its drug resistance by disrupting crucial biological processes in the TME, such as angiogenesis and immune evasion. This review evaluates the potential of inhibiting the FGF/FGFR axis as a strategy for treating TNBC. It explores the prospects for developing related therapeutic approaches. This study explores the research and application prospects of the FGF/FGFR axis in TNBC. The aim is to provide guidance for further therapeutic research and facilitate the development of innovative approaches targeting TNBC. |
| format | Article |
| id | doaj-art-c8e38cecda9640d090aa684f4919b3b4 |
| institution | DOAJ |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-c8e38cecda9640d090aa684f4919b3b42025-08-20T02:57:51ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-03-011410.3389/fonc.2024.14158201415820Therapies targeting triple-negative breast cancer: a perspective on anti-FGFRJinhao Chen0Jinhao Chen1Jinhao Chen2Qianru Wang3Qianru Wang4Hongyan Wu5Hongyan Wu6Xiaofei Huang7Xiaofei Huang8Chunyu Cao9Chunyu Cao10Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, Hubei, ChinaAffiliated Renhe Hospital of China Three Gorges University, Yichang, Hubei, ChinaCollege of Basic Medical Sciences, China Three Gorges University, Yichang, ChinaHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, Hubei, ChinaCollege of Basic Medical Sciences, China Three Gorges University, Yichang, ChinaHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, Hubei, ChinaCollege of Basic Medical Sciences, China Three Gorges University, Yichang, ChinaAffiliated Renhe Hospital of China Three Gorges University, Yichang, Hubei, ChinaCollege of Basic Medical Sciences, China Three Gorges University, Yichang, ChinaHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, Hubei, ChinaCollege of Basic Medical Sciences, China Three Gorges University, Yichang, ChinaTriple-negative breast cancer (TNBC) is one of the subtypes with the worst prognosis due to tumour heterogeneity and lack of appropriate treatment. This condition is a consequence of the distinctive tumour microenvironment (TME). The TME is associated with factors such as the promotion of proliferation, angiogenesis, inhibition of apoptosis, suppression of the immune system and drug resistance. Therefore, remodelling the TME is critical for the treatment of TNBC. A key role in the formation of the TME is played by the fibroblast growth factor/fibroblast growth factor receptor(FGF/FGFR) signalling pathway. Thus, the FGFRs may be a potential target for treating TNBC. Over-activated FGFRs promote growth, migration and drug resistance in TNBC by influencing the onset of TME events, tumour angiogenesis and immune rejection. A thorough comprehension of the FGF/FGFR signalling pathway’s mechanism of action in the development of TNBC could offer valuable insights for discovering new therapeutic strategies and drug targets. Inhibiting the FGF/FGFR axis could potentially hinder the growth of TNBC and its drug resistance by disrupting crucial biological processes in the TME, such as angiogenesis and immune evasion. This review evaluates the potential of inhibiting the FGF/FGFR axis as a strategy for treating TNBC. It explores the prospects for developing related therapeutic approaches. This study explores the research and application prospects of the FGF/FGFR axis in TNBC. The aim is to provide guidance for further therapeutic research and facilitate the development of innovative approaches targeting TNBC.https://www.frontiersin.org/articles/10.3389/fonc.2024.1415820/fullTNBCFGF/FGFR pathwaytumor microenvironmenttargeted therapiesFGFR inhibitor |
| spellingShingle | Jinhao Chen Jinhao Chen Jinhao Chen Qianru Wang Qianru Wang Hongyan Wu Hongyan Wu Xiaofei Huang Xiaofei Huang Chunyu Cao Chunyu Cao Therapies targeting triple-negative breast cancer: a perspective on anti-FGFR Frontiers in Oncology TNBC FGF/FGFR pathway tumor microenvironment targeted therapies FGFR inhibitor |
| title | Therapies targeting triple-negative breast cancer: a perspective on anti-FGFR |
| title_full | Therapies targeting triple-negative breast cancer: a perspective on anti-FGFR |
| title_fullStr | Therapies targeting triple-negative breast cancer: a perspective on anti-FGFR |
| title_full_unstemmed | Therapies targeting triple-negative breast cancer: a perspective on anti-FGFR |
| title_short | Therapies targeting triple-negative breast cancer: a perspective on anti-FGFR |
| title_sort | therapies targeting triple negative breast cancer a perspective on anti fgfr |
| topic | TNBC FGF/FGFR pathway tumor microenvironment targeted therapies FGFR inhibitor |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1415820/full |
| work_keys_str_mv | AT jinhaochen therapiestargetingtriplenegativebreastcanceraperspectiveonantifgfr AT jinhaochen therapiestargetingtriplenegativebreastcanceraperspectiveonantifgfr AT jinhaochen therapiestargetingtriplenegativebreastcanceraperspectiveonantifgfr AT qianruwang therapiestargetingtriplenegativebreastcanceraperspectiveonantifgfr AT qianruwang therapiestargetingtriplenegativebreastcanceraperspectiveonantifgfr AT hongyanwu therapiestargetingtriplenegativebreastcanceraperspectiveonantifgfr AT hongyanwu therapiestargetingtriplenegativebreastcanceraperspectiveonantifgfr AT xiaofeihuang therapiestargetingtriplenegativebreastcanceraperspectiveonantifgfr AT xiaofeihuang therapiestargetingtriplenegativebreastcanceraperspectiveonantifgfr AT chunyucao therapiestargetingtriplenegativebreastcanceraperspectiveonantifgfr AT chunyucao therapiestargetingtriplenegativebreastcanceraperspectiveonantifgfr |